CITIUS ONCOLOGY, INC.
CTORDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Hydrocortisone acetate and lidocaine hydrochloride | Phase 2 | Hemorrhoids | - | - |
Frequently asked questions
What is in CITIUS ONCOLOGY, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in CITIUS ONCOLOGY, INC.'s (CTOR) pipeline across Phase 2. Its lead program is Hydrocortisone acetate and lidocaine hydrochloride (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CITIUS ONCOLOGY, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CITIUS ONCOLOGY, INC. (CTOR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CTOR biotech catalysts?→
Add CTOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CITIUS ONCOLOGY, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.